Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
2(14%)
Results Posted
100%(7 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_2
5
36%
Ph not_applicable
1
7%
Ph phase_4
2
14%
Ph phase_1
2
14%
Ph phase_3
1
7%

Phase Distribution

2

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(3)
Completed(7)
Terminated(2)
Other(2)

Detailed Status

Completed7
Terminated2
Recruiting2
unknown2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 25 (45.5%)
Phase 31 (9.1%)
Phase 42 (18.2%)
N/A1 (9.1%)

Trials by Status

terminated214%
recruiting214%
unknown214%
not_yet_recruiting17%
completed750%

Recent Activity

2 active trials
Showing 5 of 14
recruitingphase_3

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT06439082
completedphase_2

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

NCT04611880
unknown

Managed Access Programs for SEG101, Crizanlizumab

NCT03720626
completedphase_2

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

NCT03938454
recruitingphase_4

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT04657822
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06439082Phase 3

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Recruiting
NCT04611880Phase 2

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Completed
NCT03720626

Managed Access Programs for SEG101, Crizanlizumab

Unknown
NCT03938454Phase 2

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Completed
NCT04657822Phase 4

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Recruiting
NCT03474965Phase 2

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Completed
NCT04662931Phase 4

An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients

Completed
NCT04097821Phase 1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Terminated
NCT03264989Phase 2

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Completed
NCT05020873

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

Terminated
NCT05469828Phase 1

Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia

Not Yet Recruiting
NCT05334576Not Applicable

Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA

Unknown
NCT05494541

Characteristics of Patients With Sickle Cell Disease

Completed
NCT04435184Phase 2

Crizanlizumab for Treating COVID-19 Vasculopathy

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14